John M. Wallmark

Hematology Oncology

Shady Grove Medical Building Suite200, Suite 200
Rockville, MD 20850

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 4 publications

Pembrolizumab for advanced prostate adenocarcinoma: findings of the KEYNOTE-028 study.

Pembrolizumab for advanced prostate adenocarcinoma: findings of the KEYNOTE-028 study.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: July 12, 2018

Pembrolizumab for the Treatment of Advanced Salivary Gland Carcinoma: Findings of the Phase 1b KEYNOTE-028 Study.

Pembrolizumab for the Treatment of Advanced Salivary Gland Carcinoma: Findings of the Phase 1b KEYNOTE-028 Study.

Journal: American journal of clinical oncology

Published: February 21, 2018

Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with advanced colorectal carcinoma.

Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with advanced colorectal carcinoma.

Journal: PloS one

Published: July 19, 2017

Phase Ib study of drozitumab combined with first-line mFOLFOX6 plus bevacizumab in patients with metastatic colorectal cancer.

Phase Ib study of drozitumab combined with first-line mFOLFOX6 plus bevacizumab in patients with metastatic colorectal cancer.

Journal: Cancer investigation

Published: October 16, 2012

Showing 1-4 of 4

Last Updated: 09/26/2026